Asociación entre enfermedad tromboembólica venosa y dislipidemia

Raso, Aránzazu García; Miranda, Carolina; Vidal, Rosa; Mata, Raquel; Llamas-Sillero, Pilar

doi:10.1016/j.medcli.2013.07.024

Cited by 19 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, the association between venous thrombosis and dyslipidemia had been demonstrated 33–35. Our study found that high serum level of LDL was associated with CRT, and consistent results were also reported in studies on VTE risk factors 34,35. But the relation with CRT was not observed in HDL, TC and TG, which was inconsistent with other studies that showed that low level of HDL,33,34 hypercholesterolemia36 and high level of TG33 were strong predictors for VTE.…”

Section: Discussionsupporting

confidence: 92%

“…Our study found that high serum level of LDL was associated with CRT, and consistent results were also reported in studies on VTE risk factors 34,35. But the relation with CRT was not observed in HDL, TC and TG, which was inconsistent with other studies that showed that low level of HDL,33,34 hypercholesterolemia36 and high level of TG33 were strong predictors for VTE. However, the relationship between high levels of TGs, TC, LDL cholesterol and VTE is controversial, due to different study populations (with regard to disease, age and sex) and study designs.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

<p>Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study</p>

Tan¹,

Sun²,

Zhu³

et al. 2019

CMAR

View full text Add to dashboard Cite

PurposeTotally implantable venous access devices (TIVADs) are widely used in cancer patients. The main purpose of our study is to observe the incidence and identified risk factors of catheter-related thrombosis (CRT) in breast cancer patients with TIVAD.Patients and methodsWe performed a retrospective cohort study of consecutive breast cancer patients who received the ultrasound-guided TIVAD implantation for the administration of chemotherapy from 2013 to 2016. The primary outcome was CRT (both symptomatic and asymptomatic detected by ultrasound). Univariable and multivariable logistic regression analyses were used to identify the risk factors for breast cancer TIVAD-related CRT.ResultsA total of 209 breast cancer patients with a newly implanted TIVAD for chemotherapy were included in this study. The average time of port duration was 7 months. Of the enrolled 209 patients, 33 patients (15.8%) had CRT, 2 of the 33 cases were symptomatic (1 pulmonary embolism, 1 deep-venous thrombosis [DVT]), the other 31 cases were asymptomatic detected by routine ultrasound examination of the catheter-associated vein before TIVAD removal with all cycles of chemotherapy completed. In total, 19 (57.6%) of CRT patients underwent directly TIVAD removal without any further treatments, 14 patients received anticoagulation treatments for 3–30 days followed by TIVAD removal. No DVT event was observed within at least 1.5 years of follow-up. In the multiple-variable analysis, tumor size >2 cm (OR 2.735, 95% CI 1.042–7.177; P=0.032), positive HbsAg (OR 2.803 95% CI 1.027–7.856; P=0.047) and low-density lipoprotein (LDL) >3.6 mmol/L (OR 2.360, 95% CI 1.059–5.351; P=0.040) were the significant independent risk factors of breast cancer TIVAD-related CRT.ConclusionCRT is a common complication in breast cancer patients with TIVAD for chemotherapy. Tumor size, HbsAg status and LDL level were independent predictors of breast cancer for TIVAD-related CRT. Removal of the port without anticoagulation treatments might be a feasible choice for asymptomatic TIVAD-related CRT.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

<p>Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study</p>

Tan¹,

Sun²,

Zhu³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…They also found that those with this disease might develop venous thrombosis 4-fold more. 21 No significant relations were detected between fistula thrombosis and TG level in our study. This showed that HDL-C could be the main target for protection from AVF thrombosis according to the Log (TG/HDL-C) formula.…”

Section: Discussioncontrasting

confidence: 66%

Effects of plasma atherogenic index and plasma osmolality on arteriovenous fistula patency in hemodialysis patients

2021

View full text Add to dashboard Cite

Background: The purpose of the present study was to investigate the effects of Plasma atherogenic index (AIP) and plasma osmolality (PO) values on arteriovenous fistula (AVF) patency in patients with chronic renal failure. Methods: The patients with primary AVF between December 2012 and March 2020 with the diagnosis of end-stage renal disease in our clinic were included in the study. The patient data were collected retrospectively in digital medium. Diabetic patients were not included in the study. The Triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), sodium (Na), fasting blood glucose, and blood urea nitrogen (BUN) values were found and recorded from the files. AIP and PO were calculated with special formulas. Fistula patency rate in 6th, 12th, and 24th months were evaluated in 2-year follow-ups. Results: According to the results of two-year follow-ups of the 162 patients, who underwent primary AVF, 21 (13%) patients were found to have thrombosis in the 6th month, 33 (20.4%) patients in the 12th month; however,141 (87%) and 129 (79.6%) patients actively used AVF in the 6th and 12th months, respectively. The AIP and PO values that were calculated in the patient group with AVF thrombosis were significantly higher ( p = 0.001, p < 0.001; respectively). In the multivariate logistic regression analysis, Na, BUN, and HDL-C variables were found to be independent predictive factors for AVF thrombosis (OR (Odds Ratio): 1.169, 95% CI (Confidence interval)): 1.056–1.294, p = 0.003; OR: 1.108, 95% CI: 1.043–1.176, p = 0.001; OR: 0.874, 95% CI: 0.820–0.932, p < 0.001; respectively). It was also found that the patency rate was 64.2% (104 patients) in the 24th month. Conclusion: AIP, PO, Na, and BUN values are positively associated with AVF thrombosis. Checking AIP, Na, and BUN values will be useful in patients with end-term renal failure, who already have difficulties in renal replacement methods and vascular access.

show abstract

“…Huang et al [27] demonstrated the strong link between hypertension and venous thrombosis, where this health risk increased 4 times in individuals with dyslipidemia [28]. Thus, in order to predict the protecting effects of VPH and VPH-I from thrombosis, samples were assayed for their ability to extend blood clotting times.…”

Section: Resultsmentioning

confidence: 99%

Assessment of Cholesterol, Glycemia Control and Short- and Long-Term Antihypertensive Effects of Smooth Hound Viscera Peptides in High-Salt and Fructose Diet-Fed Wistar Rats

et al. 2019

View full text Add to dashboard Cite

In this study, the antihypertensive activity of Purafect®-smooth hound viscera protein hydrolysate (VPH) and its peptide fraction with molecular weight (MW) below 1 kDa (VPH-I) was investigated. In addition, the lipase inhibitory activity, as well the anticoagulant potential, in vitro, were assessed. The antihypertensive effects of VPH and VPH-I were studied during 24 h (short-term effect) and 30 days (long-term effect) using high-salt (18% NaCl) and -fructose (10%) diet (HSFD)-induced hypertension. Data showed that, 4 h post-administration of VPH and VPH-I (200 mg/kg BW), the systolic blood pressure of rats was reduced by about 6 and 9 mmHg, respectively. These effects were similar to that obtained with Captopril (~9 mmHg at t = 4 h). On the other hand, exposing the rats to daily to HSFD, coupled to the administration of viscera peptides, was found to attenuate hypertension. In addition, the proteins’ treatments were able to correct lipid and glycemic disorders, by reducing the total cholesterol and triglyceride contents and resorting to the plasma glucose level, compared to the HSFD group. Overall, the present findings demonstrated the preventive effect of VPH-peptides from hypertension complications, as a result of their biological properties.

show abstract

Asociación entre enfermedad tromboembólica venosa y dislipidemia

Cited by 19 publications

References 25 publications

<p>Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study</p>

<p>Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study</p>

Effects of plasma atherogenic index and plasma osmolality on arteriovenous fistula patency in hemodialysis patients

Assessment of Cholesterol, Glycemia Control and Short- and Long-Term Antihypertensive Effects of Smooth Hound Viscera Peptides in High-Salt and Fructose Diet-Fed Wistar Rats

Contact Info

Product

Resources

About